← Leaderboards
Ramon E Parsons
Columbia University Health Sciences
$25,379,842
Attributed
$26,131,018
Total exposure
16
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.8M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$55,209,991 · 18
By mechanism
P30$30,877,079 · 7
R01$12,890,537 · 6
R35$6,788,076 · 1
P01$4,654,299 · 4
Top collaborators
- Jian Jin8 shared
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Cy A Stein$3,201,323
- Mehboob A Hussain$12,670,960
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsProgramsCellsTumorBaseCancer PatientCancer TherapySignal TransductionResearch PersonnelCancer Center Support GrantFamilyTranslatingMedical SchoolsTumor Suppressor ProteinsGeneticPathway InteractionsPten GenePhosphotransferasesNeoplastic CellMutateAwardCancer CellMediatingProto-Oncogene Proteins C-Akt
Grant awards (109)
The Tisch Cancer Institute - Cancer Center Support Grant$3,065,655
P30 · FY2025 · CA · contact PI
Leadership, Planning and Evaluation$231,385
P30 · FY2025 · CA · contact PI
THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANT$2,638,439
P30 · FY2024 · CA · contact PI
Developmental Funds$527,623
P30 · FY2024 · CA · contact PI
Leadership, Planning and Evaluation$294,916
P30 · FY2024 · CA · contact PI
Clonal Hematopoeisis, Biomarkers of Aging and Cancer Risk for People Living With HIV (HIV-Associated Cancers in Aging Populations)$250,000
P30 · FY2024 · CA · contact PI
THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANT$2,638,439
P30 · FY2023 · CA · contact PI
PTEN and Cancer$991,735
R35 · FY2023 · CA · contact PI
Developmental Funds$527,623
P30 · FY2023 · CA · contact PI
Leadership, Planning and Evaluation$294,916
P30 · FY2023 · CA · contact PI
How do Lay Health Navigators Impact Breast Cancer Screening? (MICEO Supplement);$200,000
P30 · FY2023 · CA · contact PI
THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANT$2,638,439
P30 · FY2022 · CA · contact PI
PTEN and Cancer$991,735
R35 · FY2022 · CA · contact PI
Developmental Funds$527,623
P30 · FY2022 · CA · contact PI
Leadership, Planning and Evaluation$294,916
P30 · FY2022 · CA · contact PI
(PQ9) Developing EZH2 Degraders for Treating Triple-Negative Breast Cancer$244,844
R01 · FY2022 · CA
(PQ9) Developing EZH2 Degraders for Treating Triple-Negative Breast Cancer$87,357
R01 · FY2022 · CA
THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANT$2,638,439
P30 · FY2021 · CA · contact PI
PTEN and Cancer$1,011,974
R35 · FY2021 · CA · contact PI
Developmental Funds$527,623
P30 · FY2021 · CA · contact PI
Leadership, Planning and Evaluation$294,916
P30 · FY2021 · CA · contact PI
THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANT$250,001
P30 · FY2021 · CA · contact PI
THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANT$249,999
P30 · FY2021 · CA · contact PI
(PQ9) Developing EZH2 Degraders for Treating Triple-Negative Breast Cancer$249,841
R01 · FY2021 · CA
(PQ9) Developing EZH2 Degraders for Treating Triple-Negative Breast Cancer$89,140
R01 · FY2021 · CA
THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANT$1
P30 · FY2021 · CA · contact PI
THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANT$2,638,439
P30 · FY2020 · CA · contact PI
PTEN and Cancer$1,011,974
R35 · FY2020 · CA · contact PI
Developmental Funds$527,623
P30 · FY2020 · CA · contact PI
Identifying immune correlates of disease severity and novel immune drivers of pathogenicity to target in patients with COVID-19$423,750
P30 · FY2020 · CA · contact PI
Leadership, Planning and Evaluation$294,916
P30 · FY2020 · CA · contact PI
THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANT$250,001
P30 · FY2020 · CA · contact PI
THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANT$249,999
P30 · FY2020 · CA · contact PI
(PQ9) Developing EZH2 Degraders for Treating Triple-Negative Breast Cancer$249,841
R01 · FY2020 · CA
(PQ9) Developing EZH2 Degraders for Treating Triple-Negative Breast Cancer$89,140
R01 · FY2020 · CA
THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANT$76,275
P30 · FY2020 · CA · contact PI
The Tisch Cancer Institute - Cancer Center Support Grant$2,373,000
P30 · FY2019 · CA · contact PI
PTEN and Cancer$981,614
R35 · FY2019 · CA · contact PI
The Tisch Cancer Institute - Cancer Center Support Grant$249,999
P30 · FY2019 · CA · contact PI
(PQ9) Developing EZH2 Degraders for Treating Triple-Negative Breast Cancer$242,348
R01 · FY2019 · CA
PTEN and Cancer$72,343
R35 · FY2019 · CA · contact PI
Cancer Mechanisms (CM) (Project-002)$13,687
P30 · FY2019 · CA · contact PI
The Tisch Cancer Institute - Cancer Center Support Grant$2,373,000
P30 · FY2018 · CA · contact PI
PTEN and Cancer$1,011,974
R35 · FY2018 · CA · contact PI
The Tisch Cancer Institute - Cancer Center Support Grant$249,999
P30 · FY2018 · CA · contact PI
(PQ9) Developing EZH2 Degraders for Treating Triple-Negative Breast Cancer$249,841
R01 · FY2018 · CA
The Tisch Cancer Institute - Cancer Center Support Grant$224,981
P30 · FY2018 · CA · contact PI
PTEN and Cancer$69,919
R35 · FY2018 · CA · contact PI
Cancer Mechanisms (CM) (Project-002)$15,129
P30 · FY2018 · CA · contact PI
The Tisch Cancer Institute - Cancer Center Support Grant$2,373,000
P30 · FY2017 · CA · contact PI
PTEN and Cancer$644,808
R35 · FY2017 · CA · contact PI
Mutual Regulation of PTEN and P-REX2a in Normal and Cancer Cells$400,192
R01 · FY2017 · CA · contact PI
Mechanisms of PTEN-Long Function in Cancer$350,652
R01 · FY2017 · CA · contact PI
Cancer Mechanisms (CM) (Project-002)$15,129
P30 · FY2017 · CA · contact PI
Mutual Regulation of PTEN and P-REX2a in Normal and Cancer Cells$400,192
R01 · FY2016 · CA · contact PI
Mechanisms of PTEN-Long Function in Cancer$350,652
R01 · FY2016 · CA · contact PI
PTEN Tumor Suppressor and Signal Transduction$254,036
R01 · FY2016 · CA · contact PI
Cancer Mechanisms (CM) (Project-002)$15,130
P30 · FY2016 · CA · contact PI
Mutual regulation of PTEN and P-REX2a in normal and cancer cells$351,713
R01 · FY2015 · CA · contact PI
Mechanisms of PTEN-Long Function in Cancer$350,652
R01 · FY2015 · CA · contact PI
PTEN Tumor Suppressor and Signal Transduction$254,036
R01 · FY2015 · CA · contact PI
Cancer Mechanisms (CM) (Project-002)$9,293
P30 · FY2015 · CA · contact PI
Mechanisms of PTEN-Long Function in Cancer$350,652
R01 · FY2014 · CA · contact PI
Mutual regulation of PTEN and P-REX2a in normal and cancer cells$341,162
R01 · FY2014 · CA · contact PI
PTEN Tumor Suppressor and Signal Transduction$246,415
R01 · FY2014 · CA · contact PI
The role of PTEN in basal-like breast cancer$273,211
P01 · FY2013 · CA · contact PI
Mutual regulation of PTEN and P-REX2a in normal and cancer cells$238,832
R01 · FY2013 · CA · contact PI
Oncogenic role of PIK3CA hotspot mutations$186,959
R01 · FY2013 · CA · contact PI
Administrative and analytical core$145,636
P01 · FY2013 · CA · contact PI
BREAST CANCER RESEARCH$136,392
P30 · FY2013 · CA · contact PI
Oncogenic role of PIK3CA hotspot mutations$127,027
R01 · FY2013 · CA · contact PI
Mutual regulation of PTEN and P-REX2a in normal and cancer cells$86,634
R01 · FY2013 · CA · contact PI
Mutual regulation of PTEN and P-REX2a in normal and cancer cells$332,000
R01 · FY2012 · CA · contact PI
Oncogenic role of PIK3CA hotspot mutations$324,053
R01 · FY2012 · CA · contact PI
The role of PTEN in basal-like breast cancer$309,812
P01 · FY2012 · CA · contact PI
PTEN Tumor Suppressor and Signal Transduction$239,798
R01 · FY2012 · CA · contact PI
PTEN Tumor Suppressor and Signal Transduction$238,795
R01 · FY2012 · CA · contact PI
Administrative and analytical core$181,876
P01 · FY2012 · CA · contact PI
BREAST CANCER RESEARCH$54,222
P30 · FY2012 · CA · contact PI
Molecular Pathogenesis of Basal-like Breast Cancer$1,196,635
P01 · FY2011 · CA · contact PI
Mutual regulation of PTEN and P-REX2a in normal and cancer cells$333,038
R01 · FY2011 · CA · contact PI
Oncogenic role of PIK3CA hotspot mutations$324,053
R01 · FY2011 · CA · contact PI
The role of PTEN in basal-like breast cancer$306,619
P01 · FY2011 · CA · contact PI
Administrative and analytical core$159,117
P01 · FY2011 · CA · contact PI
BREAST CANCER RESEARCH$60,541
P30 · FY2011 · CA · contact PI
Molecular Pathogenesis of Basal-like Breast Cancer$918,901
P01 · FY2010 · CA · contact PI
Oncogenic role of PIK3CA hotspot mutations$333,349
R01 · FY2010 · CA · contact PI
PTEN Tumor Suppressor and Signal Transduction$241,297
R01 · FY2010 · CA · contact PI
BREAST CANCER RESEARCH$61,830
P30 · FY2010 · CA · contact PI
Molecular Pathogenesis of Basal-like Breast Cancer$911,582
P01 · FY2009 · CA · contact PI
Oncogenic role of PIK3CA hotspot mutations$332,623
R01 · FY2009 · CA · contact PI
PTEN Tumor Suppressor and Signal Transduction$241,297
R01 · FY2009 · CA · contact PI
BREAST CANCER RESEARCH$61,568
P30 · FY2009 · CA · contact PI
BREAST CANCER RESEARCH$751
P30 · FY2009 · CA · contact PI
PTEN Tumor Suppressor and Signal Transduction$241,297
R01 · FY2008 · CA · contact PI
BREAST CANCER RESEARCH$37,472
P30 · FY2008 · CA · contact PI
PTEN Tumor Suppressor and Signal Transduction$241,297
R01 · FY2007 · CA · contact PI
PTEN Tumor Suppressor and Signal Transduction$248,504
R01 · FY2006 · CA · contact PI
PI-3 Kinase Therapy in Mouse Tumor Models$544,440
R01 · FY2005 · CA
PTEN TUMOR SUPPRESSOR AND SIGNAL TRANSDUCTION$267,132
R01 · FY2005 · CA
PI-3 Kinase Therapy in Mouse Tumor Models$529,918
R01 · FY2004 · CA
PTEN TUMOR SUPPRESSOR AND SIGNAL TRANSDUCTION$266,661
R01 · FY2004 · CA
PI-3 Kinase Therapy in Mouse Tumor Models$515,818
R01 · FY2003 · CA
PTEN TUMOR SUPPRESSOR AND SIGNAL TRANSDUCTION$266,206
R01 · FY2003 · CA
PI-3 Kinase Therapy in Mouse Tumor Models$505,691
R01 · FY2002 · CA
PTEN TUMOR SUPPRESSOR AND SIGNAL TRANSDUCTION$265,768
R01 · FY2002 · CA
PTEN TUMOR SUPPRESSOR AND SIGNAL TRANSDUCTION$265,344
R01 · FY2001 · CA
CHARACTERIZATION OF THE 10Q22-23 CANDIDATE TUMOR SUPPRESSOR IN BREAST CANCER$0
P01 · FY2001 · CA
CHARACTERIZATION OF THE 10Q22-23 CANDIDATE TUMOR SUPPRESSOR IN BREAST CANCER$250,910
P01 · FY2000 · CA